Assessment of lymphopenia in patients with multiple sclerosis treated with dimethyl fumarate in a real clinical setting

被引：0
|
作者：
Alroughani, Raed [1 ]
Ahmed, Samar [2 ]
Behbehani, Raed [2 ]
Al-hashel, Jasem [3 ]
机构：
[1] Amiri Hosp, Kuwait, Kuwait
[2] Ibn Sina Hosp, Kuwait, Kuwait
[3] Kuwait Univ, Kuwait, Kuwait
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
47
引用
收藏
页码：NP18 / NP18
页数：1
相关论文
共 50 条
  • [21] Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes
    Dinoto, Alessandro
    Sartori, Arianna
    Cheli, Marta
    Pasquin, Fulvio
    Baldini, Sara
    Bratina, Alessio
    Bosco, Antonio
    Manganotti, Paolo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [22] INCIDENCE OF PERSISTENT LYMPHOPENIA IN PEOPLE WITH MULTIPLE SCLEROSIS ON DIMETHYL FUMARATE
    Wood, Callum
    Pickersgill, Trevor
    Willis, Mark
    Robertson, Neil
    Tallantyre, Emma
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [23] Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate
    Wood, Callum H.
    Robertson, Neil P.
    Htet, Zin Min
    Tallantyre, Emma C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [24] Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature
    Russo, Cinzia Dello
    Scott, Kathryn Anne
    Pirmohamed, Munir
    PHARMACOLOGY & THERAPEUTICS, 2021, 219
  • [25] COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
    Vittorio Mantero
    Lucia Abate
    Paola Basilico
    Roberto Balgera
    Andrea Salmaggi
    Bardia Nourbakhsh
    Christian Cordano
    Journal of Neurology, 2021, 268 : 2023 - 2025
  • [26] Clinical characteristics of relapsing-remitting multiple sclerosis patients with persistent lymphopenia with dimethyl fumarate and comparison with no lymphopenic patients
    Lopez Ruiz, R.
    Eichau, S.
    Perez Gamez, M.
    Navarro Mascarell, G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Izquierdo, G.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 921 - 922
  • [27] Lymphopenia in patients on dimethyl fumarate (DMF): data from the providence multiple sclerosis center
    Smoot, K. E.
    Chen, C.
    Baraban, E.
    Grote, L.
    Kresa-Reahl, K.
    Cohan, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 292 - 293
  • [28] Prevalence and predictors of lymphopenia in multiple sclerosis (MS) patients treated with fingolimod (FG) or delayed - release dimethyl fumarate (DMF)
    Baharnoori, M.
    Chua, A.
    Diaz-Cruz, C.
    Healy, B. C.
    Stankiewicz, J.
    Weiner, H. L.
    Chitnis, T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 354 - 355
  • [29] Persistent lymphopenia after routine clinical use of dimethyl fumarate for relapsing remitting multiple sclerosis
    MacDougall, N. J.
    Gallagher, P.
    Murdoch, S.
    Murray, L.
    Webb, S.
    Overell, J. R.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 300 - 300
  • [30] Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, Maryam
    Barilla, David
    Lee, Chieh-Hsin
    Blevins, Gregg
    Giuliani, Fabrizio
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2018, 5 (02):
12345